Streetbeat News

Analyst Ratings

AVDX

Susquehanna analyst James Friedman has initiated coverage on AvidXchange Holdings (NASDAQ:AVDX) with a positive rating and a price target of $15.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 1:39 pm

RBB

Piper Sandler analyst Nicholas Cucharale has assumed RBB Bancorp (NASDAQ:RBB) with a Neutral rating and set a price target of $14.5.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 1:37 pm

AR

Morgan Stanley analyst Devin McDermott has maintained an Equal-Weight rating on Antero Resources (NYSE:AR) and lowered the price target from $24 to $23.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 1:37 pm

TARS

William Blair has initiated coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with an Outperform rating and a price target of $44.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 1:36 pm

MO

Morgan Stanley analyst Pamela Kaufman has reiterated an Equal-Weight rating on Altria Group (NYSE:MO) and maintained a $45 price target.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 1:36 pm

RBLX

Traders are circulating a note from M Science suggesting that Roblox Corporation is raising its Q2 bookings outlook due to a stronger quarter-end than previously anticipated.

Portfolio Pulse from Happy Mohamed

July 18, 2023 | 1:35 pm

LPX

TD Cowen analyst Sean Steuart has downgraded Louisiana-Pacific (NYSE:LPX) from Buy to Hold, while raising the price target from $75 to $85.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 1:34 pm

CYRX

UBS analyst John Sourbeer has downgraded CryoPort (NASDAQ:CYRX) from Buy to Neutral and lowered the price target from $28 to $17.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 1:34 pm

AMWD

Sidoti & Co. has downgraded American Woodmark (NASDAQ:AMWD) from Buy to Neutral, while raising the price target from $71 to $79.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 1:33 pm

ABBV

AbbVie's (NYSE:ABBV) short percent of float has fallen 7.81% since its last report, with 10.36 million shares sold short, which is 0.59% of all regular shares available for trading. This decrease in short interest could signal a more bullish sentiment towards the stock. AbbVie's short interest as a percentage of float is lower than its peer group average of 3.62%.

Portfolio Pulse from Benzinga Insights

July 18, 2023 | 1:30 pm